April 23, 2019 06:29 AM EDT

Lilly to sell legacy antibiotics, Ceclor and Vancocin, to China-based partner in $375M deal

Natalie Grover

Reporter

More than two years after Lilly partnered with specialty drugmaker Eddingpharm to exclusively distribute its decades-old antibiotics — Ceclor and Vancocin — in mainland China, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly to sell legacy antibiotics, Ceclor and Vancocin, to China-based partner in $375M deal

Natalie Grover

Reporter

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Applied Therapeutics' rare disease drug gets a CRL

Lil­ly to sell lega­cy an­tibi­otics, Ce­clor and Van­cocin, to Chi­na-based part­ner in $375M deal

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Lilly to sell legacy antibiotics, Ceclor and Vancocin, to China-based partner in $375M deal

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Applied Therapeutics' rare disease drug gets a CRL